Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The objective of the study is to determine the dose(s) of Ro 205-2349 which, when compared to placebo, are efficacious, safe and tolerable in improving glycemic control in patients with type 2 diabetes. Doses of 2 to 5 mg/day will be studied.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| RO 205-2349 2 mg QD | Experimental | RO 205-2349 2 mg was taken once daily (QD) for 16 weeks during the double-blind treatment period. |
|
| RO 205-2349 5 mg QD | Experimental | RO 205-2349 5 mg was taken once daily (QD) for 16 weeks during the double-blind treatment period. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| RO 205-2349 | Drug |
|
|
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hollywood | Florida | 33021 | United States | |||
Not provided
All potential participants entered the placebo run-in phase. At the end of the placebo run-in phase, eligible participants who met the final inclusion/exclusion criteria were randomized to the double-blind treatment period.
treatment
Not provided
Not provided
Not provided
| Durham |
| North Carolina |
| 27710 |
| United States |
| Morrisville | North Carolina | 27560 | United States |
| Portland | Oregon | 97219 | United States |
| Portland | Oregon | 97239 | United States |
| Camp Hill | Pennsylvania | 17011 | United States |
| Greer | South Carolina | 29651 | United States |
| Memphis | Tennessee | 38119 | United States |
| Memphis | Tennessee | 38163 | United States |
| Dallas | Texas | 75230 | United States |
| Houston | Texas | 77030 | United States |
| Midland | Texas | 79705 | United States |
| Lebanon | Virginia | 24266 | United States |
| Virginia Beach | Virginia | 23451 | United States |
| Pleven | 5800 | Bulgaria |
| Plovdiv | 4002 | Bulgaria |
| Sofia | 1233 | Bulgaria |
| Sofia | 1431 | Bulgaria |
| Sofia | 1606 | Bulgaria |
| Tallinn | 10138 | Estonia |
| Tartu | 50406 | Estonia |
| Tartu | 50708 | Estonia |
| Võru | 65609 | Estonia |
| Chihuahua, Chih. | Mexico |
| Guadalajara | 44349 | Mexico |
| Guadalajara, JAL. | 44340 | Mexico |
| Mexico City | 06700 | Mexico |
| Mérida | 97000 | Mexico |
| Monterrey | 64320 | Mexico |
| Monterrey | 64410 | Mexico |
| Monterrey | 64460 | Mexico |
| Pachuca, Hidalgo | 42039 | Mexico |
| Panama City | Panama |
| Ponce | 00732-7994 | Puerto Rico |
| Arad | 2900 | Romania |
| Brasov | 500326 | Romania |
| Bucharest | 020475 | Romania |
| Bucharest | 7000 | Romania |
| Craiova | 1100 | Romania |
| Galati | 6200 | Romania |
| Ploieşti | 2000 | Romania |
| Targoviste | 0200 | Romania |
| Târgu Mureş | 4300 | Romania |
| Meyrin | 1217 | Switzerland |
| Bracknell | RG12 1HX | United Kingdom |
| Nottingham | NG2 3HF | United Kingdom |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| ID | Term |
|---|---|
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C403084 | BM 13.1258 |
Not provided
Not provided
Not provided